Home Cart Sign in  
Chemical Structure| 1632006-28-0 Chemical Structure| 1632006-28-0

Structure of Esaxerenone
CAS No.: 1632006-28-0

Chemical Structure| 1632006-28-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Esaxerenone is an aldosterone receptor antagonist. Esaxerenone may be potential useful for preventing or treating hypertension or disease caused by hypertension.

Synonyms: CS-3150; XL-550

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Esaxerenone

CAS No. :1632006-28-0
Formula : C22H21F3N2O4S
M.W : 466.47
SMILES Code : O=C(C1=CN(CCO)C(C2=CC=CC=C2C(F)(F)F)=C1C)NC3=CC=C(S(=O)(C)=O)C=C3
Synonyms :
CS-3150; XL-550
MDL No. :N/A

Safety of Esaxerenone

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02448628 Hypertension PHASE2 COMPLETED 2025-12-15 Osaka, 530-0001, Japan
NCT02885662 Primary Aldosteronism COMPLETED 2017-07-20 Japan Organaization of Occupat... More >>ional Health and Safety(JOHAS), Yokohama Rosai Hospital, Yokohama, Kanagawa, 222-0036, Japan Less <<
NCT02722265 Essential Hypertension PHASE3 COMPLETED 2017-07-08 Osaka, Japan
NCT02807987 Hypertension With Moderate Ren... More >>al Impairment Less << PHASE3 COMPLETED 2017-05-15 Nagano, Japan
NCT02808026 Severe Hypertension PHASE3 COMPLETED 2025-02-17 Sapporo, Japan
NCT02807974 Hypertension PHASE3 COMPLETED 2025-03-17 Sanuki-shi, Kagawa, Japan

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.14mL

0.43mL

0.21mL

10.72mL

2.14mL

1.07mL

21.44mL

4.29mL

2.14mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories